Acetylcholinesterase inhibition affects cardiovascular structure in mice.

Experiments were performed in C57BL/6J male mice to determine the effects of acetylcholinesterase (AChE) inhibitor pyridostigmine bromide (PB) and stress on cardiovascular function, structure, and apoptosis. Mice were studied for seven days under the following conditions: Controls (osmotic minipump with saline), PB (10 mg/kg/day, minipumps), shaker stress (45 stressors/day, minipump with saline) and PB+Stress combination. AChE activity was significantly reduced in all PB-treated mice. PB caused no changes in 24-h mean arterial pressure (MAP) or heart rate (HR). Stress increased 24-h MAP on day 1 and 24-h HR on day 7 in both Stress and PB+Stress groups. A significant reduction in the aortic wall thickness/diameter ratio (P <0.05 vs. control) and slightly reduced relative heart weight were observed in the PB group. These effects were blunted by simultaneous stress exposure. Immunochemistry was used to stain for Bax and Bcl-2 (apoptosis markers). There was a four-fold increase in Bax/Bcl-2 ratio in the heart of PB and PB+Stress treated mice while an attenuation was observed in aortic endothelium. Results suggest that a relatively short-term continuous PB exposure may have adverse effects on the heart and blood vessels, independently of changes in MAP and HR.

[1]  R. S. Moraes,et al.  Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects , 2001, Clinical Autonomic Research.

[2]  Andrea Grabe-Guimarães M.Sc.,et al.  Pyridostigmine blunts the increases in myocardial oxygen demand elicited by the stimulation of the central nervous system in anesthetized rats , 2006, Clinical Autonomic Research.

[3]  S. Raj,et al.  Acetylcholinesterase Inhibition Improves Tachycardia in Postural Tachycardia Syndrome , 2005, Circulation.

[4]  M. Morris,et al.  Acute and chronic stress influence blood pressure variability in mice , 2004, Physiology & Behavior.

[5]  R. Haley,et al.  Blunted circadian variation in autonomic regulation of sinus node function in veterans with Gulf War syndrome. , 2004, The American journal of medicine.

[6]  M. Morris,et al.  Stress‐induced pressor and corticosterone responses in oxytocin‐deficient mice , 2004, Experimental physiology.

[7]  M. Morris,et al.  Enhanced heart rate variability and baroreflex index after stress and cholinesterase inhibition in mice. , 2004, American journal of physiology. Heart and circulatory physiology.

[8]  P. Soares,et al.  Cholinergic stimulation with pyridostigmine increases heart rate variability and baroreflex sensitivity in rats , 2004, Autonomic Neuroscience.

[9]  J. Zicha,et al.  Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. , 2004, Physiological research.

[10]  T. Ozawa,et al.  Role of acetylcholine in pyridostigmine-induced myocardial injury: possible involvement of parasympathetic nervous system in the genesis of cardiomyopathy , 2004, Archives of Toxicology.

[11]  C. Sueta.  Heart rate variability in chronic heart failure: target for therapy? , 2003, American heart journal.

[12]  E. Mesquita,et al.  Cardiac function during mental stress: cholinergic modulation with pyridostigmine in healthy subjects. , 2003, Clinical science.

[13]  R. Servatius,et al.  Stress interacts with peripheral cholinesterase inhibitors to cause central nervous system effects. , 2003, Life sciences.

[14]  M. Morris,et al.  Effect of chronic pyridostigmine bromide treatment on cardiovascular and behavioral parameters in mice , 2003, Pharmacology Biochemistry and Behavior.

[15]  M. Arese,et al.  The molecular mechanisms by which nitric oxide controls mitochondrial complex IV. , 2003, The Italian journal of biochemistry.

[16]  M. Morris,et al.  Circadian Differences in Stress-Induced Pressor Reactivity in Mice , 2002, Hypertension.

[17]  H. Otani,et al.  Nitric oxide induces caspase-dependent apoptosis and necrosis in neonatal rat cardiomyocytes. , 2002, Journal of molecular and cellular cardiology.

[18]  A. Nóbrega,et al.  Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary artery disease. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[19]  F. Kristek,et al.  Beneficial effect of pentaerythrityl tetranitrate on functional and morphological changes in the rat thoracic aorta evoked by long-term nitric oxide synthase inhibition. , 2002, Vascular pharmacology.

[20]  P. Babál,et al.  Expression of proliferation and apoptotic markers in human placenta during pregnancy. , 2002, Acta histochemica.

[21]  Lei Yang,et al.  Induction of acetylcholinesterase expression during apoptosis in various cell types , 2002, Cell Death and Differentiation.

[22]  B. McManus,et al.  Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. , 2001, Journal of molecular and cellular cardiology.

[23]  M. Quik,et al.  Nitric oxide is involved in acetylcholinesterase inhibitor-induced myopathy in rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[24]  M. Dikshit,et al.  Immobilization stress-induced changes in brain acetylcholinesterase activity and cognitive function in mice. , 2000, Pharmacological research.

[25]  R. Haley,et al.  Stressful manipulations that elevate corticosterone reduce blood-brain barrier permeability to pyridostigmine in the Rat. , 2000, Toxicology and applied pharmacology.

[26]  Shing-Hwa Liu,et al.  Nitric oxide prevents apoptosis of human endothelial cells from high glucose exposure during early stage , 1999, Journal of cellular biochemistry.

[27]  D. Sawyer,et al.  Cytokine-mediated apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and peroxynitrite generation. , 1999, Circulation research.

[28]  A. Nóbrega,et al.  Pyridostigmine blunts the increases in myocardial oxygen demand elicited by the stimulation of the central nervous system in anesthetized rats , 1999, Clinical autonomic research : official journal of the Clinical Autonomic Research Society.

[29]  Ping Li,et al.  Circadian blood pressure and heart rate rhythms in mice. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[30]  K. Webster,et al.  Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. , 1999, Circulation research.

[31]  P. Babál,et al.  L-NAME-induced protein remodeling and fibrosis in the rat heart. , 1999, Physiological research.

[32]  O. Pechanova,et al.  Mechanism of structural remodelling of the rat aorta during long-term NG-nitro-L-arginine methyl ester treatment. , 1999, Japanese journal of pharmacology.

[33]  F. Adatia,et al.  Increased Expression of Acetylcholinesterase T and R Transcripts during Hematopoietic Differentiation Is Accompanied by Parallel Elevations in the Levels of Their Respective Molecular Forms* , 1998, The Journal of Biological Chemistry.

[34]  M. Nehls,et al.  Shear stress inhibits apoptosis of human endothelial cells , 1996, FEBS letters.

[35]  J. Balligand,et al.  Nitric oxide and cardiac function. , 1996, Circulation research.

[36]  P. Taylor,et al.  Regulation of Acetylcholinesterase Expression during Neuronal Differentiation (*) , 1996, The Journal of Biological Chemistry.

[37]  D. Jezova,et al.  Vasopressin and Oxytocin in Stress a , 1995, Annals of the New York Academy of Sciences.

[38]  M. Callahan,et al.  Oxytocin antisense reduces salt intake in the baroreceptor-denervated rat , 1995, Regulatory Peptides.

[39]  D. Gordon,et al.  Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. , 1995, Circulation research.

[40]  A. Hassid,et al.  Mechanisms of nitrosothiol-induced antimitogenesis in aortic smooth muscle cells. , 1993, European journal of pharmacology.

[41]  J R Keeler,et al.  Pyridostigmine used as a nerve agent pretreatment under wartime conditions. , 1991, JAMA.

[42]  U. Maier,et al.  Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis , 1985, Clinical pharmacology and therapeutics.